% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pickl:130330,
      author       = {J. M. A. Pickl$^*$ and D. Tichy$^*$ and V. Kuryshev$^*$ and
                      Y. Tolstov and M. Falkenstein and J. Schüler and D.
                      Reidenbach$^*$ and A. Hotz-Wagenblatt$^*$ and G. Kristiansen
                      and W. Roth and B. Hadaschik and M. Hohenfellner and S.
                      Duensing and D. Heckmann$^*$ and H. Sültmann$^*$},
      title        = {{A}go-{RIP}-{S}eq identifies {P}olycomb repressive complex
                      {I} member {CBX}7 as a major target of mi{R}-375 in prostate
                      cancer progression.},
      journal      = {OncoTarget},
      volume       = {7},
      number       = {37},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2017-05409},
      pages        = {59589 - 59603},
      year         = {2016},
      abstract     = {Prostate cancer is a heterogeneous disease. MiR-375 is a
                      marker for prostate cancer progression, but its cellular
                      function is not characterized. Here, we provide the first
                      comprehensive investigation of miR-375 in prostate cancer.
                      We show that miR-375 is enriched in prostate cancer compared
                      to normal cells. Furthermore, miR-375 enhanced
                      proliferation, migration and invasion in vitro and induced
                      tumor growth and reduced survival in vivo showing that
                      miR-375 has oncogenic properties in prostate cancer. On the
                      molecular level, we provide the targetome and genome-wide
                      transcriptional changes of miR-375 expression by applying a
                      generalized linear model for Ago-RIP-Seq and RNA-Seq, and
                      show that miR-375 is involved in tumorigenic networks and
                      Polycomb regulation. Integration of tissue and gene ontology
                      data prioritized miR-375 targets and identified the tumor
                      suppressor gene CBX7, a member of Polycomb repressive
                      complex 1, as a major miR-375 target. MiR-375-mediated
                      repression of CBX7 was accompanied by increased expression
                      of its homolog CBX8 and activated transcriptional programs
                      linked to malignant progression in prostate cancer cells.
                      Tissue analysis showed association of CBX7 loss with
                      advanced prostate cancer. Our study indicates that miR-375
                      exerts its tumor-promoting role in prostate cancer by
                      influencing the epigenetic regulation of transcriptional
                      programs through its ability to directly target the Polycomb
                      complex member CBX7.},
      cin          = {B063 / C060 / W180 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)B063-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)W180-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27449098},
      pmc          = {pmc:PMC5312160},
      doi          = {10.18632/oncotarget.10729},
      url          = {https://inrepo02.dkfz.de/record/130330},
}